DADC
AVEO

D.A. Davidson & Co’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

D.A. Davidson & Co’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed -$2K – 2211
2017
Q2 		$2K Hold
100
– – ﹤0.01% 2309
2017
Q1 		$0 Buy
+100
New +$722 ﹤0.01% 2548
2014
Q1 		– Sell
-8
Closed – – 2238
2013
Q4 		$0 Buy
+8
New +$160 ﹤0.01% 2156

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.A. Davidson & Co's AVEO Position: Q3 2017 in Review

D.A. Davidson & Co sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q3 2017, closing a stake of 100 shares — an estimated $2K sold.

D.A. Davidson & Co first reported a position in AVEO in Q4 2013 and held it in 3 quarters. The position peaked at $2K in Q2 2017. 57 funds tracked by Wall St. Rank hold AVEO as of Q3 2017.

  • D.A. Davidson & Co reported no remaining AVEO Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • D.A. Davidson & Co sold 100 AVEO Pharmaceuticals, Inc. shares in Q3 2017, an estimated $2K.
  • D.A. Davidson & Co first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2013 and held it in 3 quarters.
  • D.A. Davidson & Co's AVEO Pharmaceuticals, Inc. position peaked at $2K in Q2 2017.
  • 57 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q3 2017.

Based on D.A. Davidson & Co's 13F filing for Q3 2017, filed 8 Nov 2017.